CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Diagnosis and Treatment of Sacroiliac Joint Pain

Defines medical necessity criteria, covered and not-covered procedures, prior authorization expectations, and CPT coding for diagnostic intra-articular SIJ injections, corticosteroid injections, radiofrequency denervation, and minimally-invasive sacroiliac joint (SIJ) fusion for Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Diagnosis and Treatment of Sacroiliac Joint Pain

Policy CodePolicy N/A

Change Typeclarified

Effective DateJan 1, 2011

Next Review Date

Key ActionObtain prior authorization (Medicare Advantage required; recommended for Commercial) and document ≥75% pain reduction after two separate image-guided, contrast-enhanced intra-articular SIJ anesthetic injections plus at least one therapeutic corticosteroid SIJ injection.

SourceLink

POLICY UPDATE CHANGES

Policy last updated 04/07/2021; effective date listed as 11/01 (year not specified).

3Primary coverage positions (fusion, injections, RFA)

>=75%Required pain reduction after diagnostic injections

6 monthsRequired nonoperative treatment duration

Coverage Summary

This policy defines medical necessity criteria, covered and not-covered procedures, prior authorization expectations, and CPT coding for diagnostic image-guided intra-articular SIJ anesthetic injections, therapeutic corticosteroid intra-articular SIJ injections, radiofrequency denervation/ablation (RFA), and minimally invasive sacroiliac joint (SIJ) fixation/fusion for Medicare Advantage and Commercial products. Coverage stance is mixed and the policy status is CURRENT. Key objective thresholds include ≥75% pain reduction after two separate image-guided, contrast-enhanced intra-articular SIJ anesthetic injections (different-duration anesthetics) and a minimum of ≥6 months of intensive nonoperative treatment prior to MIS SIJ fusion. CPT coding guidance lists 27279 for MIS SIJ fusion and covers G0260 and 27096 for diagnostic/therapeutic SIJ injections; no specific CPT code exists for RFA (use an appropriate unlisted CPT code).

Key thresholds and quick facts

Diagnostic injection pain reduction>= 75% reduction of pain for the expected duration of two anesthetics (separate visits, different durations)

Non-operative treatment duration>= 6 months of intensive non-operative treatment (medication optimization, activity modification, bracing, targeted active therapeutic exercise and home program)

Primary coverage positions count3 (MIS SIJ fusion, diagnostic/therapeutic SIJ injections, radiofrequency denervation status specified)

Not Medically Necessary / Not Covered Procedures

Multiple randomized controlled trials and systematic reviews support minimally invasive SIJ fusion versus conservative management in selected trials, with several RCTs and longer-term follow-up studies reported. In contrast, evidence for radiofrequency ablation (RFA) is inconsistent: small RCTs and series have reported short-term or mixed results and some sham-controlled trials showed no benefit, leaving the evidence insufficient to determine net health benefit. This differential evidence base underpins the policy position that MIS SIJ fusion can be medically necessary when criteria are met while RFA is not covered/not medically necessary due to insufficient evidence.

Provider Actions & Documentation Requirements

Prior Authorization

Prior authorization is required

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products for MIS SIJ fusion and related procedures.

Documentation Required

Document diagnostic response to intra-articular SIJ injections

Document at least 75% pain reduction after two separate image-guided, contrast-enhanced intra-articular SIJ anesthetic injections (on separate visits each using a different duration anesthetic) and document at least one therapeutic intra-articular corticosteroid SIJ injection.

Affected codes: G0260
Affected codes: 27096

Documentation Required

Imaging requirements

Provide imaging that includes an AP pelvis plain radiograph to rule out concomitant hip pathology, and CT or MRI of the SI joint and lumbar spine to exclude destructive lesions (tumor, infection), fracture, traumatic SIJ instability, inflammatory arthropathy, neural compression, or other degenerative conditions.

Denial Risk

Radiofrequency denervation not covered/medically unnecessary

Claims for radiofrequency denervation/ablation of the sacroiliac joint may be denied or considered not medically necessary: not covered for Medicare Advantage Plans and not medically necessary for Commercial Products due to insufficient evidence.

Background & Definitions

Scope: the policy addresses diagnostic and therapeutic use of image-guided intra-articular SIJ anesthetic injections for diagnosis, corticosteroid injections for treatment, radiofrequency ablation (RFA) for neurotomy/denervation, and minimally invasive percutaneous or indirect-visualization SIJ fixation/fusion. Several percutaneous and minimally invasive SIJ fixation/fusion devices have been cleared by the FDA via 510(k) (for example, iFuse, Rialto, SImmetry, Silex, SambaScrew, SI-LOK), and multiple radiofrequency generators and probes have been cleared for marketing; nevertheless, the clinical evidence supports MIS SIJ fusion in selected patients while evidence for RFA is inconsistent and insufficient.

Term	Definition
{"text":"Fortin's point","status":""},{"text":"Localized tenderness at the insertion of the long dorsal ligament inferior to the posterior superior iliac spine (PSIS).","status":""}

RCTs and systematic reviews: Multiple randomized controlled trials, systematic reviews, and case series have evaluated minimally invasive SIJ fusion versus non-surgical/conservative management and report benefit in selected trials and follow-up periods. By contrast, RFA for SIJ pain has been assessed in several small RCTs and case series with mixed short-term results; some sham-controlled trials found no benefit, and overall the evidence for RFA is inconsistent and insufficient.

Name	Number	Type	Effective Date
{"text":"Minimally-invasive Surgical (MIS) Fusion of the Sacroiliac (SI) Joint","status":""},{"text":"L36406","status":""},{"text":"LCD","status":""},{"text":"","status":""}

Revision History

2011-01-01Updated

Policy effective date listed as 11/01 (EFFECTIVE DATE: 11 |01).

2021-04-07UpdatedLatest

Policy last updated 04/07/2021; document header notes 'POLICY LAST UPDATED: 04|07 2021'.